| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Jul―06 |
Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice |
Mianling Yang, Meehyein Kim, Peng Zhan |
| 2 |
[GO] |
2024―May―31 |
Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics |
Chris Chun-Yiu Chan, Qian Guo, Jasper Fuk-Woo Chan, Kaiming Tang, Jian-Piao Cai, Kenn Ka-Heng Chik, Yixin Huang, Mei Dai, Bo Qin, Chon Phin Ong, Allen Wing-Ho Chu, Wan-Mui Chan, Jonathan Daniel Ip, Lei Wen, Jessica Oi-Ling Tsang, Tong-Yun Wang, Yubin Xie, Zhenzhi Qin, Jianli Cao, Zi-Wei Ye, Hin Chu, Kelvin Kai-Wang To, Xing-Yi Ge, Tao Ni, Dong-Yan Jin, Sheng Cui, Kwok-Yung Yuen, Shuofeng Yuan |
| 3 |
[GO] |
2024―May―22 |
SARS-CoV-2 ORF10 hijacking ubiquitination machinery reveals potential unique drug targeting sites |
Kaixiang Zhu, Lili Song, Linyue Wang, Lei Hua, Ziyu Luo, Tongyun Wang, Bo Qin, Shuofeng Yuan, Xiaopan Gao, Wenyi Mi, Sheng Cui |
| 4 |
[GO] |
2024―Apr―15 |
Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2 |
Miao Zheng, Bo Feng, Yumin Zhang, Xin Liu, Na Zhao, Hui Liu, Zichao Xu, Xinheng He, Zhiyan Qu, Shizhao Chen, Zhidong Jiang, Xi Cheng, Hong Liu, Yi Zang, Linxiang Zhao, Jie Zheng, Leike Zhang, Jia Li, Yu Zhou |
| 5 |
[GO] |
2024―Mar―12 |
Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein |
Xiafei Wei, Yuzheng Zhou, Xiaotong Shen, Lujie Fan, Donglan Liu, Xiang Gao, Jian Zhou, Yezi Wu, Yunfei Li, Wei Feng, Zheng Zhang |
| 6 |
[GO] |
2024―Mar―06 |
Development of an active-site titrant for SARS-CoV-2 main protease as an indispensable tool for evaluating enzyme kinetics |
Rabea Voget, Julian Breidenbach, Tobias Claff, Alexandra Hingst, Katharina Sylvester, Christian Steinebach, Lan Phuong Vu, Renato H. Weiße, Ulrike Bartz, Norbert Sträter, Christa E. Müller, Michael Gütschow |
| 7 |
[GO] |
2024―Mar―03 |
Carrimycin inhibits coronavirus replication by decreasing the efficiency of programmed -1 ribosomal frameshifting through directly binding to the RNA pseudoknot of viral frameshift-stimulatory element |
Hongying Li, Jianrui Li, Jiayu Li, Hu Li, Xuekai Wang, Jing Jiang, Lei Lei, Han Sun, Mei Tang, Biao Dong, Weiqing He, Shuyi Si, Bin Hong, Yinghong Li, Danqing Song, Zonggen Peng, Yongsheng Che, Jian-Dong Jiang |
| 8 |
[GO] |
2024―Feb―13 |
Bile acids and coronavirus disease 2019 |
Xiaoru Huang, Xuening Liu, Zijian Li |
| 9 |
[GO] |
2023―Aug―25 |
Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSVMT) in golden syrian hamster |
Yong Ke, En Zhang, Jianming Guo, Xiaoxiao Zhang, Lei Wang, Duo Chen, Xinkui Fang, Jianwei Zhu, Feng Li, Tao Sun, Baohong Zhang |
| 10 |
[GO] |
2023―Aug―09 |
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors |
Letian Song, Shenghua Gao, Bing Ye, Mianling Yang, Yusen Cheng, Dongwei Kang, Fan Yi, Jin-Peng Sun, Luis Menéndez-Arias, Johan Neyts, Xinyong Liu, Peng Zhan |
| 11 |
[GO] |
2023―Aug―08 |
Corrigendum to Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles |
Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, Mingjie Shi, Hong Qiu, Yongzhuo Huang |
| 12 |
[GO] |
2023―Jul―13 |
Clinical Trials Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study |
Kaican Zong, Hui Zhou, Wen Li, E. Jiang, Yi Liu, Shiying Li |
| 13 |
[GO] |
2023―May―27 |
HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration |
Ying Lu, Fan Shen, Wenqiang He, Anqi Li, Minghua Li, Xiaoli Feng, Yongtang Zheng, Wei Pang |
| 14 |
[GO] |
2023―Apr―18 |
SARS-CoV-2 spike host cell surface exposure promoted by a COPI sorting inhibitor |
Yiqun Li, Mingrui Yang, Yanan Nan, Jiaming Wang, Sanjiao Wang, Dongxiao Cui, Jiajian Guo, Pengfei He, Wenxin Dai, Shuqi Zhou, Yue Zhang, Wenfu Ma |
| 15 |
[GO] |
2023―Feb―24 |
Application of microfluidic technologies on COVID-19 diagnosis and drug discovery |
Zhun Lin, Zhengyu Zou, Zhe Pu, Minhao Wu, Yuanqing Zhang |
| 16 |
[GO] |
2023―Feb―23 |
A micro-sized vaccine based on recombinant Lactiplantibacillus plantarum fights against SARS-CoV-2 infection via intranasal immunization |
Letian Li, Jiayi Hao, Yuhang Jiang, Pengfei Hao, Yuwei Gao, Jing Chen, Guoqing Zhang, Ningyi Jin, Maopeng Wang, Chang Li |
| 17 |
[GO] |
2023―Feb―21 |
Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19 |
Zhicheng Liu, Zhuolei Han, Xin Jin, Jusung An, Jaewon Kim, Wenting Chen, Jong Seung Kim, Ji Zheng, Jun Deng |
| 18 |
[GO] |
2023―Feb―09 |
Can FXR serve as a potential target for COVID-19 prevention? |
Juan Pang, Jia Nuo Feng, Wenhua Ling, Tianru Jin |
| 19 |
[GO] |
2023―Jan―12 |
A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants |
Shugang Qin, Hai Huang, Wen Xiao, Kepan Chen, Xi He, Xiaoshan Tang, Zhiying Huang, Yupei Zhang, Xing Duan, Na Fan, Qian Zheng, Min Wu, Guangwen Lu, Yuqan Wei, Xiawei Wei, Xiangrong Song |
| 20 |
[GO] |
2022―Nov―21 |
Mucosal delivery of nanovaccine strategy against COVID-19 and its variants |
Junwoo Lee, Dongwoo Khang |
| 21 |
[GO] |
2022―Sep―23 |
Localized delivery of nanomedicine and antibodies for combating COVID-19 |
Bin Tu, Yanrong Gao, Xinran An, Huiyuan Wang, Yongzhuo Huang |
| 22 |
[GO] |
2022―Aug―09 |
Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19 |
Yang Yi, Meng Zhang, Heng Xue, Rong Yu, Yang-Oujie Bao, Yi Kuang, Yue Chai, Wen Ma, Jing Wang, Xiaomeng Shi, Wenzhe Li, Wei Hong, Junhua Li, Elishiba Muturi, Hongping Wei, Joachim Wlodarz, Szczepan Roszak, Xue Qiao, Hang Yang, Min Ye |
| 23 |
[GO] |
2022―Jul―22 |
Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity |
Fuhua Wu, Shuang Luo, Yongshun Zhang, Yangsen Ou, Hairui Wang, Zhaofei Guo, Chunting He, Shuting Bai, Penghui He, Min Jiang, Xiaoyan Chen, Guangsheng Du, Xun Sun |
| 24 |
[GO] |
2022―Jun―09 |
Acrylamide fragment inhibitors that induce unprecedented conformational distortions in enterovirus 71 3C and SARS-CoV-2 main protease |
Bo Qin, Gregory B. Craven, Pengjiao Hou, Julian Chesti, Xinran Lu, Emma S. Child, Rhodri M.L. Morgan, Wenchao Niu, Lina Zhao, Alan Armstrong, David J. Mann, Sheng Cui |
| 25 |
[GO] |
2022―Jun―06 |
Rapid screening of SARS-CoV-2 inhibitors via ratiometric fluorescence of RBD-ACE2 complexes in living cells by competitive binding |
Lu Miao, Wei Zhou, Chunyu Yan, Yuebin Zhang, Qinglong Qiao, Xuelian Zhou, Yingzhu Chen, Guangying Wang, Zhendong Guo, Jun Liu, Hailong Piao, Xia Pan, Mengxue Yan, Weijie Zhao, Guohui Li, Yueqing Li, Zhaochao Xu |
| 26 |
[GO] |
2022―Apr―08 |
Viral miRNA-mediated activation of hyaluronan production as a drug target against COVID-19 |
Shuai Yang, Lu Chen, Ying Tong, Wenqiang Yu |
| 27 |
[GO] |
2022―Feb―28 |
Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2 |
Saba R. Aliyari, Amir Ali Ghaffari, Olivier Pernet, Kislay Parvatiyar, Yao Wang, Hoda Gerami, Ann-Jay Tong, Laurent Vergnes, Armin Takallou, Adel Zhang, Xiaochao Wei, Linda D. Chilin, Yuntao Wu, Clay F. Semenkovich, Karen Reue, Stephen T. Smale, Benhur Lee, Genhong Cheng |
| 28 |
[GO] |
2022―Feb―11 |
Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants |
Bin Tu, Huiyuan Wang, Xinran An, Jingkun Qu, Qianqian Li, Yanrong Gao, Mingjie Shi, Hong Qiu, Yongzhuo Huang |
| 29 |
[GO] |
2021―Nov―01 |
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays |
Chunlong Ma, Haozhou Tan, Juliana Choza, Yuying Wang, Jun Wang |
| 30 |
[GO] |
2021―Sep―20 |
Traditional Chinese medicine in COVID-19 |
Ming Lyu, Guanwei Fan, Guangxu Xiao, Taiyi Wang, Dong Xu, Jie Gao, Shaoqin Ge, Qingling Li, Yuling Ma, Han Zhang, Jigang Wang, Yuanlu Cui, Junhua Zhang, Yan Zhu, Boli Zhang |
| 31 |
[GO] |
2021―Sep―09 |
Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles |
Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, Mingjie Shi, Hong Qiu, Yongzhuo Huang |
| 32 |
[GO] |
2021―Aug―31 |
Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors |
Shenghua Gao, Tianguang Huang, Letian Song, Shujing Xu, Yusen Cheng, Srinivasulu Cherukupalli, Dongwei Kang, Tong Zhao, Lin Sun, Jian Zhang, Peng Zhan, Xinyong Liu |
| 33 |
[GO] |
2021―Aug―02 |
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases |
Jie Zhou, Wei Xu, Zezhong Liu, Chao Wang, Shuai Xia, Qiaoshuai Lan, Yanxing Cai, Shan Su, Jing Pu, Lixiao Xing, Youhua Xie, Lu Lu, Shibo Jiang, Qian Wang |
| 34 |
[GO] |
2021―Jul―02 |
Recent advances in developing small-molecule inhibitors against SARS-CoV-2 |
Rong Xiang, Zhengsen Yu, Yang Wang, Lili Wang, Shanshan Huo, Yanbai Li, Ruiying Liang, Qinghong Hao, Tianlei Ying, Yaning Gao, Fei Yu, Shibo Jiang |
| 35 |
[GO] |
2021―May―13 |
SARS-CoV-2 cell entry and targeted antiviral development |
Zinuo Chen, Ruikun Du, Jazmin M. Galvan Achi, Lijun Rong, Qinghua Cui |
| 36 |
[GO] |
2021―Mar―12 |
Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2 |
Haiyan Yan, Jing Sun, Kun Wang, Huiqiang Wang, Shuo Wu, Linlin Bao, Weiqing He, Dong Wang, Airu Zhu, Tian Zhang, Rongmei Gao, Biao Dong, Jianrui Li, Lu Yang, Ming Zhong, Qi Lv, Feifei Qin, Zhen Zhuang, Xiaofang Huang, Xinyi Yang, Yuhuan Li, Yongsheng Che, Jiandong Jiang |
| 37 |
[GO] |
2021―Feb―16 |
Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase |
Quanjie Li, Dongrong Yi, Xiaobo Lei, Jianyuan Zhao, Yongxin Zhang, Xiangling Cui, Xia Xiao, Tao Jiao, Xiaojing Dong, Xuesen Zhao, Hui Zeng, Chen Liang, Lili Ren, Fei Guo, Xiaoyu Li, Jianwei Wang, Shan Cen |
| 38 |
[GO] |
2020―Nov―16 |
Neutralizing antibodies for the treatment of COVID-19 |
Zeqi Zhou, Xiangbin Wang, Yankai Fu, Xiqing Zhang, Changxiao Liu |
| 39 |
[GO] |
2020―Oct―13 |
Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator |
Jingwei Bian, Zijian Li |
| 40 |
[GO] |
2020―Sep―07 |
Letter to the Editor: Increased plasma ACE2 concentration does not mean increased risk of SARS-CoV-2 infection and increased fatality rate of COVID-19 |
Xue-Ting Li, Ying Liu, Juan-Juan Song, Jiu-Chang Zhong |
| 41 |
[GO] |
2020―Sep―02 |
Crystal structure of SARS-CoV-2 papain-like protease |
Xiaopan Gao, Bo Qin, Pu Chen, Kaixiang Zhu, Pengjiao Hou, Justyna Aleksandra Wojdyla, Meitian Wang, Sheng Cui |
| 42 |
[GO] |
2020―Aug―18 |
Editor Profiles: Guest Editors of Special Column “Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)” |
|
| 43 |
[GO] |
2020―Aug―18 |
Editorial of Special Column “Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)” |
Hai-Bin Luo, Shilin Chen, Peiqing Liu |
| 44 |
[GO] |
2020―Jun―27 |
Combating COVID-19 with integrated traditional Chinese and Western medicine in China |
Liqiang Ni, Weian Yuan, Lili Chen, Chouping Han, Hong Zhang, Xin Luan, Yongfang Zhao, Jianguang Xu, Hongzhuan Chen |
| 45 |
[GO] |
2020―Jun―08 |
Bioactive natural compounds against human coronaviruses: a review and perspective |
Yanfang Xian, Juan Zhang, Zhaoxiang Bian, Hua Zhou, Zhenbiao Zhang, Zhixiu Lin, Hongxi Xu |
| 46 |
[GO] |
2020―May―30 |
Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight |
Chunting He, Ming Qin, Xun Sun |
| 47 |
[GO] |
2020―May―27 |
Analysis on herbal medicines utilized for treatment of COVID-19 |
Lu Luo, Jingwen Jiang, Cheng Wang, Martin Fitzgerald, Weifeng Hu, Yumei Zhou, Hui Zhang, Shilin Chen |
| 48 |
[GO] |
2020―May―27 |
Letter to the Editor: Comment on GLP-1-based drugs and COVID-19 treatment |
Tianru Jin, Mingyao Liu |
| 49 |
[GO] |
2020―Apr―29 |
Anti-RAS drugs and SARS-CoV-2 infection |
Jingwei Bian, Rongsheng Zhao, Suodi Zhai, Zijian Li |
| 50 |
[GO] |
2020―Apr―21 |
Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites |
Sisi Kang, Mei Yang, Zhongsi Hong, Liping Zhang, Zhaoxia Huang, Xiaoxue Chen, Suhua He, Ziliang Zhou, Zhechong Zhou, Qiuyue Chen, Yan Yan, Changsheng Zhang, Hong Shan, Shoudeng Chen |
| 51 |
[GO] |
2020―Apr―20 |
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 |
Xiaoyan Liu, Zhe Li, Shuai Liu, Jing Sun, Zhanghua Chen, Min Jiang, Qingling Zhang, Yinghua Wei, Xin Wang, Yi-You Huang, Yinyi Shi, Yanhui Xu, Huifang Xian, Fan Bai, Changxing Ou, Bei Xiong, Andrew M. Lew, Jun Cui, Rongli Fang, Hui Huang, Jincun Zhao, Xuechuan Hong, Yuxia Zhang, Fuling Zhou, Hai-Bin Luo |
| 52 |
[GO] |
2020―Apr―20 |
D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19 |
Yulong Shi, Xinben Zhang, Kaijie Mu, Cheng Peng, Zhengdan Zhu, Xiaoyu Wang, Yanqing Yang, Zhijian Xu, Weiliang Zhu |
| 53 |
[GO] |
2020―Apr―20 |
Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model |
Cheng Cui, Miao Zhang, Xueting Yao, Siqi Tu, Zhe Hou, Valerie Sia Jie En, Xiaoqiang Xiang, Jing Lin, Ting Cai, Ning Shen, Chunli Song, Jie Qiao, Shun Zhang, Haiyan Li, Dongyang Liu |
| 54 |
[GO] |
2020―Feb―27 |
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods |
Canrong Wu, Yang Liu, Yueying Yang, Peng Zhang, Wu Zhong, Yali Wang, Qiqi Wang, Yang Xu, Mingxue Li, Xingzhou Li, Mengzhu Zheng, Lixia Chen, Hua Li |
|
